person · Reporting owner

Reinsdorf Judith A

Disclosed activity across 7 companies

Tapewire entity: 34155
SEC CIK: 0001305361

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Enpro Inc.NPO · Entity 3782	Director	September 30, 2026	October 01, 2026
Johnson Controls International plcJCI · Entity 2940	Executive VP & General Counsel	October 12, 2017	October 16, 2017
Nurix Therapeutics, Inc.NRIX · Entity 1156	Director	May 15, 2026	May 15, 2026
Toll Brothers, Inc.TOL · Entity 3421	Director	January 19, 2026	January 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Enpro Inc.

Report date September 30, 2026 · Filed October 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	1,276.327	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 91.4256 · Balance 1,276.327 F1: 1-for-1 F2: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3: Upon retirement F4: These shares do not have an expiration date and they are exercisable upon retirement

Filing footnotes · ownership attribution and instrument terms

F1: 1-for-1

F2: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc.

F3: Upon retirement

F4: These shares do not have an expiration date and they are exercisable upon retirement

Johnson Controls International plc

Report date October 12, 2017 · Filed October 16, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	300,749	Reported balance After 2017-10-12 transaction · row 1 1 source row Row 1 · 2017-10-12 · Tax withholding · Disposed 766 · Balance 300,749

Nurix Therapeutics, Inc.

Report date May 15, 2026 · Filed May 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14	Direct	31,250	Reported balance After 2026-05-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Toll Brothers, Inc.

Report date January 19, 2026 · Filed January 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,295	Reported balance After 2026-01-19 transaction · row 1 1 source row Row 1 · 2026-01-19 · Exercise / conversion · Acquired 1,295 · Balance 1,295
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2025-12-19	Direct	0	Reported balance After 2026-01-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-19 · Exercise / conversion · Disposed 1,295 · Balance 0 F1: These restricted stock units vested 100% on December 19, 2025. Settlement of 100% of these shares occurred on January 19, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units vested 100% on December 19, 2025. Settlement of 100% of these shares occurred on January 19, 2026.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALEXION PHARMACEUTICALS, INC.

Report date July 21, 2021 · Filed July 23, 2021

Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2021-07-21 transaction · row 1 1 source row Row 1 · 2021-07-21 · Disposition to issuer · Disposed 14,150 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,635 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,635 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.

Cornerstone Building Brands, Inc.

Report date July 25, 2022 · Filed July 27, 2022

Section 16 reporting ended · disclosed 2022-07-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.01 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2022-07-25 transaction · row 1 1 source row Row 1 · 2022-07-25 · Disposition to issuer · Disposed 6,850 · Balance 0 F1: Disposed of in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of March 5, 2022 (the "Merger Agreement"), by and among the Issuer, Camelot Return Intermediate Holdings, LLC ("Parent") and Camelot Return Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a subsidiary of Parent (the "Surviving Corporation"). F2: At the effective time of the Merger (the "Effective Time"), in accordance with the Merger Agreement, each share of Issuer common stock, par value $0.01 per share (a "Share") outstanding immediately prior to the Effective Time of the Merger (other than certain excluded shares), was converted into the right to receive cash in an amount equal to $24.65 in cash per Share (the "Merger Consideration"), without interest and subject to any required withholding taxes. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any Shares.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of March 5, 2022 (the "Merger Agreement"), by and among the Issuer, Camelot Return Intermediate Holdings, LLC ("Parent") and Camelot Return Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a subsidiary of Parent (the "Surviving Corporation").

F2: At the effective time of the Merger (the "Effective Time"), in accordance with the Merger Agreement, each share of Issuer common stock, par value $0.01 per share (a "Share") outstanding immediately prior to the Effective Time of the Merger (other than certain excluded shares), was converted into the right to receive cash in an amount equal to $24.65 in cash per Share (the "Merger Consideration"), without interest and subject to any required withholding taxes. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any Shares.

DUN & BRADSTREET CORP/NW

Report date February 08, 2019 · Filed February 12, 2019

Section 16 reporting ended · disclosed 2019-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-02-08 transaction · row 1 1 source row Row 1 · 2019-02-08 · Disposition to issuer · Disposed 6,500.6866 · Balance 0 F1: Cancelled pursuant to the merger agreement between The Dun & Bradstreet Corporation, Star Parent L.P. and Star Merger Sub, Inc., in exchange for the merger consideration price of $145.00 per share.
Non-Qualified Stock Option - right to buySEC Table II · derivative / convertible security · Conversion / exercise price $98.54 · Expires 2023-06-12	Direct	0	Reported balance After 2019-02-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-02-08 · Disposition to issuer · Disposed 1,387 · Balance 0 F2: Cancelled pursuant to the merger agreement in exchange for a cash payment for each share equal to the difference between the merger consideration price of $145.00 per share and the exercise price of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Cancelled pursuant to the merger agreement between The Dun & Bradstreet Corporation, Star Parent L.P. and Star Merger Sub, Inc., in exchange for the merger consideration price of $145.00 per share.

F2: Cancelled pursuant to the merger agreement in exchange for a cash payment for each share equal to the difference between the merger consideration price of $145.00 per share and the exercise price of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2026 Filed Oct 1, 2026 21:58 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	91.4256	$306.26	$28,000.00	Disclosure SEC source: 0001225208-26-008042 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,276.327 Underlying: Common Stock · 91.4256 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
September 16, 2026 Filed Sep 17, 2026 22:08 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.8384	$287.16	$240.75	Disclosure SEC source: 0001225208-26-007866 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,184.9014 Underlying: Common Stock · 0.8384 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 30, 2026 Filed Jul 1, 2026 20:39 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	74	$376.93	$27,892.82	Disclosure SEC source: 0001225208-26-006286 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,184.063 Underlying: Common Stock · 74 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
June 17, 2026 Filed Jun 18, 2026 18:48 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.5962	$363.62	$216.79	Disclosure SEC source: 0001225208-26-006116 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,110.063 Underlying: Common Stock · 0.5962 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
May 15, 2026 Filed May 15, 2026 21:52 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	GrantDirector Stock Option (right to buy) · Derivative	31,250	$0.00 Strike: $15.86	$0.00	Disclosure SEC source: 0001305361-26-000002 · wk-form4_1778881977.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document
March 31, 2026 Filed Apr 2, 2026 17:04 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	111.7096	$250.65	$28,000.01	Disclosure SEC source: 0001225208-26-004155 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,109.4668 Underlying: Common Stock · 111.7096 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
March 18, 2026 Filed Mar 19, 2026 18:47 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.7215	$250.59	$180.80	Disclosure SEC source: 0001225208-26-003861 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 997.7572 Underlying: Common Stock · 0.7215 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
February 12, 2026 Filed Feb 12, 2026 22:51 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	567	$246.91	$139,997.97	Disclosure SEC source: 0001225208-26-001827 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,038 F1 · kind: Shares acquired pursuant to the Enpro Inc. 2020 Equity Compensation Plan (as amended and restated). Read SEC document
January 19, 2026 Filed Jan 20, 2026 22:22 UTC	Toll Brothers, Inc. TOL · Entity 3421	Exercise / conversionRestricted Stock Units · Derivative	1,295	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000794170-26-000024 · form4.xml · derivative · entry 2 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,295 shares Expires 2025-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These restricted stock units vested 100% on December 19, 2025. Settlement of 100% of these shares occurred on January 19, 2026. Read SEC document
January 19, 2026 Filed Jan 20, 2026 22:22 UTC	Toll Brothers, Inc. TOL · Entity 3421	Exercise / conversionCommon Stock	1,295	$0.00	$0.00	Disclosure SEC source: 0000794170-26-000024 · form4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 31, 2025 Filed Jan 5, 2026 18:29 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	128.4267	$214.13	$27,500.01	Disclosure SEC source: 0001225208-26-000119 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 997.0357 Underlying: Common Stock · 128.4267 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
December 22, 2025 Filed Dec 23, 2025 21:34 UTC	Toll Brothers, Inc. TOL · Entity 3421	GrantRestricted Stock Units · Derivative	1,423	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000794170-25-000127 · form4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,423 Underlying: Common Stock · 1,423 shares Expires 2026-12-22 F1 · derivative.exercise_date: These restricted stock units vest 100% on December 22, 2026. Settlement of 100% of these shares will occur on January 22, 2027. Read SEC document
December 17, 2025 Filed Dec 18, 2025 19:00 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.6586	$205.19	$135.14	Disclosure SEC source: 0001225208-25-010138 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868.609 Underlying: Common Stock · 0.6586 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
September 30, 2025 Filed Oct 1, 2025 19:02 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	121.6814	$226.00	$27,500.00	Disclosure SEC source: 0001225208-25-008173 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 867.9504 Underlying: Common Stock · 121.6814 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
September 17, 2025 Filed Sep 18, 2025 18:19 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.4465	$217.89	$97.29	Disclosure SEC source: 0001225208-25-008058 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746.269 Underlying: Common Stock · 0.4465 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 30, 2025 Filed Jul 1, 2025 18:12 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	143.5656	$191.55	$27,499.99	Disclosure SEC source: 0001225208-25-006231 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745.8225 Underlying: Common Stock · 143.5656 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
June 18, 2025 Filed Jun 20, 2025 18:13 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.2835	$185.86	$52.69	Disclosure SEC source: 0001225208-25-006072 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602.2569 Underlying: Common Stock · 0.2835 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
May 19, 2025 Filed May 19, 2025 21:32 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	GrantDirector Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $9.51	$0.00	Disclosure SEC source: 0001549595-25-000076 · wk-form4_1747690334.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document
March 31, 2025 Filed Apr 1, 2025 18:50 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	169.9734	$161.79	$27,500.00	Disclosure SEC source: 0001225208-25-003761 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 601.9734 Underlying: Common Stock · 169.9734 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
February 13, 2025 Filed Feb 13, 2025 20:41 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	685	$182.27	$124,854.95	Disclosure SEC source: 0001225208-25-001644 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,471 F1 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. Read SEC document
December 19, 2024 Filed Dec 20, 2024 21:48 UTC	Toll Brothers, Inc. TOL · Entity 3421	GrantRestricted Stock Units · Derivative	1,295	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-24-029903 · form4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,295 Underlying: Common Stock · 1,295 shares Expires 2025-12-19 F1 · derivative.exercise_date: These restricted stock units vest 100% on December 19, 2025. Settlement of 100% of these shares will occur on January 20, 2026. Read SEC document
May 20, 2024 Filed May 20, 2024 23:25 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	GrantDirector Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $16.19	$0.00	Disclosure SEC source: 0001549595-24-000065 · wk-form4_1716247512.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-19 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 20, 2025, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document
February 15, 2024 Filed Feb 15, 2024 21:37 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	803	$155.66	$124,994.98	Disclosure SEC source: 0001225208-24-002158 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,786 F1 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. Read SEC document
May 04, 2023 Filed May 4, 2023 23:58 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	GrantDirector Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $9.44	$0.00	Disclosure SEC source: 0001209191-23-027510 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 4, 2024, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document
February 16, 2023 Filed Feb 17, 2023 17:26 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	942	$116.69	$109,921.98	Disclosure SEC source: 0001225208-23-002196 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,983 F1 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. Read SEC document
September 14, 2022 Filed Sep 15, 2022 19:14 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	1	$90.25	$90.25	Disclosure SEC source: 0001225208-22-010343 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the 2020 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
July 25, 2022 Filed Jul 27, 2022 01:41 UTC	Cornerstone Building Brands, Inc. CNR · Entity 125134	Disposition to issuerCommon Stock, $0.01 par value	6,850	$24.65	$168,852.50	Disclosure SEC source: 0001104659-22-082915 · tm2221436-14_4seq1.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of March 5, 2022 (the "Merger Agreement"), by and among the Issuer, Camelot Return Intermediate Holdings, LLC ("Parent") and Camelot Return Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a subsidiary of Parent (the "Surviving Corporation"). F2 · price: At the effective time of the Merger (the "Effective Time"), in accordance with the Merger Agreement, each share of Issuer common stock, par value $0.01 per share (a "Share") outstanding immediately prior to the Effective Time of the Merger (other than certain excluded shares), was converted into the right to receive cash in an amount equal to $24.65 in cash per Share (the "Merger Consideration"), without interest and subject to any required withholding taxes. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any Shares. Read SEC document
June 15, 2022 Filed Jun 16, 2022 18:28 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	1	$87.50	$87.50	Disclosure SEC source: 0001225208-22-008156 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the 2020 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
May 05, 2022 Filed May 6, 2022 21:41 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	GrantDirector Stock Option (right to buy) · Derivative	17,500	$0.00 Strike: $10.39	$0.00	Disclosure SEC source: 0001209191-22-027667 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-04 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 5, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document
March 16, 2022 Filed Mar 17, 2022 19:59 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	1	$106.51	$106.51	Disclosure SEC source: 0001225208-22-004830 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the 2020 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
February 15, 2022 Filed Feb 16, 2022 19:14 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	1,041	$105.64	$109,971.24	Disclosure SEC source: 0001225208-22-002249 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 F1 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. Read SEC document
December 15, 2021 Filed Dec 16, 2021 22:19 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	1	$108.31	$108.31	Disclosure SEC source: 0001225208-21-015071 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the 2020 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
October 01, 2021 Filed Oct 4, 2021 21:16 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	GrantDirector Stock Option (right to buy) · Derivative	35,000	$0.00 Strike: $31.24	$0.00	Disclosure SEC source: 0001209191-21-059062 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-09-30 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning November 1, 2021 until the option is fully vested on October 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
September 15, 2021 Filed Sep 17, 2021 20:07 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	1	$82.96	$82.96	Disclosure SEC source: 0001225208-21-012457 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the 2020 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:54 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	427	$86.17	$36,795.44	Disclosure SEC source: 0001225208-21-011967 · doc4.xml · derivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427 Underlying: Common Stock · 427 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. F3 · derivative.exercise_date: The reporting person elected to defer receipt of shares underlying the award. In accordance with her deferral election, the shares will be delivered to the reporting person in five annual installments commencing at Separation from Service. F3 · derivative.expiration_date: The reporting person elected to defer receipt of shares underlying the award. In accordance with her deferral election, the shares will be delivered to the reporting person in five annual installments commencing at Separation from Service. Read SEC document
August 19, 2021 Filed Aug 20, 2021 21:07 UTC	Cornerstone Building Brands, Inc. CNR · Entity 125134	GrantCommon Stock, $0.01 par value	6,850	$0.00	$0.00	Disclosure SEC source: 0001225033-21-000062 · edgar.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Read SEC document
July 21, 2021 Filed Jul 23, 2021 16:49 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Disposition to issuerCommon Stock, par value $.0001 per share	14,150	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000074 · wf-form4_162707337473264.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,635 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. Read SEC document
May 20, 2021 Filed May 24, 2021 16:32 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	673	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000044 · wf-form4_162188831573151.xml · nonDerivative · entry 2 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,150 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu ofthe annual cash retainer that the director was entitled to receive for service as a director. Read SEC document
May 20, 2021 Filed May 24, 2021 16:32 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	1,962	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000044 · wf-form4_162188831573151.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,477 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date. Read SEC document
May 14, 2020 Filed May 18, 2020 17:17 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	595	$0.00	$0.00	Disclosure SEC source: 0000899866-20-000047 · wf-form4_158983662159622.xml · nonDerivative · entry 2 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,515 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu of the annual cash retainer that the director was entitled to receive for service as a director. Read SEC document
May 14, 2020 Filed May 18, 2020 17:17 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	3,468	$0.00	$0.00	Disclosure SEC source: 0000899866-20-000047 · wf-form4_158983662159622.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,920 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the earlier of (i) the first anniversary of the grant date and (ii) the date of the 2021 Annual Shareholder Meeting. Read SEC document
May 15, 2019 Filed May 17, 2019 16:27 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	467	$0.00	$0.00	Disclosure SEC source: 0000899866-19-000065 · wf-form4_155812485861287.xml · nonDerivative · entry 2 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,452 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu of a portion of the annual cash retainer that the director was entitled to receive for service as a director. Read SEC document
May 15, 2019 Filed May 17, 2019 16:27 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	2,726	$0.00	$0.00	Disclosure SEC source: 0000899866-19-000065 · wf-form4_155812485861287.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,985 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date. Read SEC document
February 08, 2019 Filed Feb 12, 2019 13:27 UTC	DUN & BRADSTREET CORP/NW DNB · Entity 160376	Disposition to issuerNon-Qualified Stock Option - right to buy · Derivative	1,387	$0.00 Strike: $98.54	$0.00	Disclosure SEC source: 0001209191-19-009206 · doc4.xml · derivative · entry 2 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,387 shares Expires 2023-06-12 F2 · derivative.exercise_price: Cancelled pursuant to the merger agreement in exchange for a cash payment for each share equal to the difference between the merger consideration price of $145.00 per share and the exercise price of the option. F2 · shares: Cancelled pursuant to the merger agreement in exchange for a cash payment for each share equal to the difference between the merger consideration price of $145.00 per share and the exercise price of the option. F2 · derivative.underlying_shares: Cancelled pursuant to the merger agreement in exchange for a cash payment for each share equal to the difference between the merger consideration price of $145.00 per share and the exercise price of the option. Read SEC document
February 08, 2019 Filed Feb 12, 2019 13:27 UTC	DUN & BRADSTREET CORP/NW DNB · Entity 160376	Disposition to issuerCommon Stock	6,500.6866	$145.00	$942,599.56	Disclosure SEC source: 0001209191-19-009206 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Cancelled pursuant to the merger agreement between The Dun & Bradstreet Corporation, Star Parent L.P. and Star Merger Sub, Inc., in exchange for the merger consideration price of $145.00 per share. Read SEC document
September 07, 2018 Filed Sep 11, 2018 17:33 UTC	DUN & BRADSTREET CORP/NW DNB · Entity 160376	GrantCommon Stock	21.0929	$142.91	$3,014.39	Disclosure SEC source: 0001209191-18-050536 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500.6866 F1 · shares: Acquired pursuant to a dividend reinvestment feature of the issuer's stock incentive plan in connection with restricted stock units held by the reporting person. Read SEC document
June 08, 2018 Filed Jun 12, 2018 17:40 UTC	DUN & BRADSTREET CORP/NW DNB · Entity 160376	GrantCommon Stock	22.7979	$131.70	$3,002.48	Disclosure SEC source: 0001209191-18-037284 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,479.5937 F1 · shares: Acquired pursuant to a dividend reinvestment feature of the issuer's stock incentive plan in connection with restricted stock units held by the reporting person. Read SEC document
May 09, 2018 Filed May 11, 2018 16:15 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	2,174	$0.00	$0.00	Disclosure SEC source: 0000899866-18-000095 · wf-form4_152606965411680.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,259 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Award vests on the anniversary of the grant date. Read SEC document
May 08, 2018 Filed May 10, 2018 17:19 UTC	DUN & BRADSTREET CORP/NW DNB · Entity 160376	GrantCommon Stock	1,168	$0.00	$0.00	Disclosure SEC source: 0001209191-18-029329 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,456.7958 F1 · shares: Restricted Stock Units granted to Non-Employee Directors. Read SEC document
March 09, 2018 Filed Mar 13, 2018 17:29 UTC	DUN & BRADSTREET CORP/NW DNB · Entity 160376	GrantCommon Stock	18.6886	$127.48	$2,382.42	Disclosure SEC source: 0001209191-18-019306 · doc4.xml · nonDerivative · entry 1 Reinsdorf Judith A · CIK 0001305361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,288.7958 F1 · shares: Acquired pursuant to a dividend reinvestment feature of the issuer's stock incentive plan in connection with restricted stock units held by the reporting person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.